Peter R. E. Johnson

2.7k citations
54 papers · 2.3k · 1 hit paper · h-index 24

Impact in

  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research
    • Multiple Myeloma Research and Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 5%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment
    • Chronic Lymphocytic Leukemia Research

Papers in

    • Acute Myeloid Leukemia Research 17
    • Multiple Myeloma Research and Treatments 10
    • Hematopoietic Stem Cell Transplantation 6
    • Chronic Myeloid Leukemia Treatments 4
    • Chronic Lymphocytic Leukemia Research 7

Peter R. E. Johnson

52 papers receiving 2.1k citations

Peter R. E. Johnson's Hit Papers

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 2019 · 316 citations
3160+2+4Years since publication100200300

Peers

Peter R. E. Johnson
Comparison fields: 5 of 95
  • Hematology 1.4k
  • Genetics 368
  • Oncology 552
  • Immunology 252
  • Pathology and Forensic Medicine 204
Replace LILIAN M. REICH with:
LILIAN M. REICH United States
Kiyoshi Kitano Japan
Kimo C. Stine United States
Albert Grañena Spain
Kazuo Dan Japan
Steve Schey United Kingdom
Matthew J. Olnes United States
Atsuo Maruta Japan
Renée M. Y. Barge Netherlands
Masamitsu Yanada Japan
Peter R. E. Johnson relative to LILIAN M. REICH United States LILIAN M. REICH's profile →
Citations per field
00.5×2×3.3×
LILIAN M. REICH · 1×
Citations per year

Countries citing papers authored by Peter R. E. Johnson

Since Specialization
Citations

This map shows the geographic impact of Peter R. E. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter R. E. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter R. E. Johnson more than expected).

Fields of papers citing papers by Peter R. E. Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter R. E. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter R. E. Johnson. The network helps show where Peter R. E. Johnson may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter R. E. Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter R. E. Johnson Line = papers co-authored together Peter R. E. Johnson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Hit paper breakdown →
2019316
2 2008213
3 2015155
4 2011139
5 2020134
6 200591
7 199287
8 201086
9 201779
10 199576
11 200675
12 201368
13 199166
14 199351
15 200850
16 200649
17 200047
18 201843
19 201741
20 200641

About Peter R. E. Johnson

Peter R. E. Johnson is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health, having authored 54 papers that have together received 2.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (17 papers), Multiple Myeloma Research and Treatments (10 papers), Acute Lymphoblastic Leukemia research (9 papers), Chronic Lymphocytic Leukemia Research (7 papers), Hematopoietic Stem Cell Transplantation (6 papers), Lymphoma Diagnosis and Treatment (6 papers), Neutropenia and Cancer Infections (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). The work is most often cited by research in Hematology (1.4k citations), Genetics (368 citations), Oncology (552 citations), Immunology (252 citations) and Pathology and Forensic Medicine (204 citations). Peter R. E. Johnson has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include J. A. Liu Yin, John A. Liu Yin, P. Huw Roddie, J A Tooth, Nigel H. Russell, Christine J. Harrison, Tessa L. Holyoake, Khalid Tobal, Man‐Chiu Poon and Carolyn Owen. Their work appears in journals such as Blood, British Journal of Haematology, Bone Marrow Transplantation, Journal of Antimicrobial Chemotherapy and Mayo Clinic Proceedings.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact